330 related articles for article (PubMed ID: 16422891)
1. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.
El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA
J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
Gerstenbluth RE; Maniam PN; Corty EW; Seftel AD
J Androl; 2002; 23(6):922-6. PubMed ID: 12399540
[TBL] [Abstract][Full Text] [Related]
3. [Choice of treatment of erectile dysfunction associated with hypogonadism].
Aliaev IuG; Vinarov AZ; Akhvlediani ND
Urologiia; 2010; (4):37-8, 40-2. PubMed ID: 20967981
[TBL] [Abstract][Full Text] [Related]
4. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
Svetec DA; Canby ED; Thompson IM; Sabanegh ES
J Urol; 1997 Nov; 158(5):1775-7. PubMed ID: 9334599
[TBL] [Abstract][Full Text] [Related]
5. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only.
Yassin AA; Saad F
J Sex Med; 2007 Mar; 4(2):497-501. PubMed ID: 17367445
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
7. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
9. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
10. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
Permpongkosol S; Tantirangsee N; Ratana-olarn K
J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
12. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
Mulhall JP; Valenzuela R; Aviv N; Parker M
Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
[TBL] [Abstract][Full Text] [Related]
13. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
14. The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction.
Corona G; Boddi V; Lotti F; Gacci M; Carini M; De Vita G; Sforza A; Forti G; Mannucci E; Maggi M
J Sex Med; 2010 Jan; 7(1 Pt 1):284-92. PubMed ID: 19912506
[TBL] [Abstract][Full Text] [Related]
15. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
16. Can testosterone level be a good predictor of late-onset hypogonadism?
Heidari R; Sajadi H; Pourmand A; Pourmand G
Andrologia; 2015 May; 47(4):433-7. PubMed ID: 24773173
[TBL] [Abstract][Full Text] [Related]
17. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
18. [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency].
Morgunov LIu; Vertkin AL; Pushkar' DIu
Urologiia; 2007; (5):49-51. PubMed ID: 18254226
[TBL] [Abstract][Full Text] [Related]
19. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
Guay AT; Perez JB; Fitaihi WA; Vereb M
Endocr Pract; 2000; 6(2):132-8. PubMed ID: 11421528
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
